Logo image of ADOC.PA

ADOCIA SAS (ADOC.PA) Stock Fundamental Analysis

EPA:ADOC - FR0011184241 - Common Stock

7.91 EUR
-0.06 (-0.75%)
Last: 9/5/2025, 9:00:22 AM
Fundamental Rating

2

Taking everything into account, ADOC scores 2 out of 10 in our fundamental rating. ADOC was compared to 74 industry peers in the Biotechnology industry. ADOC has a bad profitability rating. Also its financial health evaluation is rather negative. ADOC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADOC has reported negative net income.
ADOC had a negative operating cash flow in the past year.
ADOC had negative earnings in each of the past 5 years.
In the past 5 years ADOC always reported negative operating cash flow.
ADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

ADOC has a Return On Assets (-34.50%) which is in line with its industry peers.
Industry RankSector Rank
ROA -34.5%
ROE N/A
ROIC N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADOC.PA Yearly ROA, ROE, ROICADOC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

ADOC has a better Gross Margin (87.98%) than 83.78% of its industry peers.
ADOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADOC.PA Yearly Profit, Operating, Gross MarginsADOC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADOC has more shares outstanding than it did 1 year ago.
ADOC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADOC has been reduced compared to a year ago.
ADOC.PA Yearly Shares OutstandingADOC.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ADOC.PA Yearly Total Debt VS Total AssetsADOC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of 0.62, we must say that ADOC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ADOC (0.62) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.62
ROIC/WACCN/A
WACC7.55%
ADOC.PA Yearly LT Debt VS Equity VS FCFADOC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.08 indicates that ADOC should not have too much problems paying its short term obligations.
ADOC's Current ratio of 1.08 is on the low side compared to the rest of the industry. ADOC is outperformed by 71.62% of its industry peers.
ADOC has a Quick Ratio of 1.07. This is a normal value and indicates that ADOC is financially healthy and should not expect problems in meeting its short term obligations.
ADOC's Quick ratio of 1.07 is on the low side compared to the rest of the industry. ADOC is outperformed by 68.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.07
ADOC.PA Yearly Current Assets VS Current LiabilitesADOC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

ADOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.43%, which is quite impressive.
ADOC shows a strong growth in Revenue. In the last year, the Revenue has grown by 333.49%.
Measured over the past years, ADOC shows a very strong growth in Revenue. The Revenue has been growing by 34.18% on average per year.
EPS 1Y (TTM)66.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.28%
Revenue 1Y (TTM)333.49%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%1682.03%

3.2 Future

The Earnings Per Share is expected to decrease by -35.06% on average over the next years. This is quite bad
Based on estimates for the next years, ADOC will show a very negative growth in Revenue. The Revenue will decrease by -18.40% on average per year.
EPS Next Y-69.76%
EPS Next 2Y-63.12%
EPS Next 3Y-27.26%
EPS Next 5Y-35.06%
Revenue Next Year-53.12%
Revenue Next 2Y-30.63%
Revenue Next 3Y-42.95%
Revenue Next 5Y-18.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ADOC.PA Yearly Revenue VS EstimatesADOC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
ADOC.PA Yearly EPS VS EstimatesADOC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADOC. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 4.33, the valuation of ADOC can be described as very cheap.
98.65% of the companies in the same industry are more expensive than ADOC, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.63. ADOC is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 4.33
ADOC.PA Price Earnings VS Forward Price EarningsADOC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADOC.PA Per share dataADOC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

ADOC's earnings are expected to decrease with -27.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.12%
EPS Next 3Y-27.26%

More info and screens

0

5. Dividend

5.1 Amount

ADOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADOCIA SAS

EPA:ADOC (9/5/2025, 9:00:22 AM)

7.91

-0.06 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14
Earnings (Next)09-25 2025-09-25
Inst Owners14.87%
Inst Owner ChangeN/A
Ins Owners9.82%
Ins Owner ChangeN/A
Market Cap144.59M
Analysts85
Price Target10.2 (28.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.67%
PT rev (3m)9.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-58.94%
EPS NY rev (3m)-58.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-42.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.33
P/S 15.51
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)1.83
Fwd EY23.08%
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.51
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.98%
FCFM N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.02%
Cap/Sales 2.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.07
Altman-Z 0.62
F-Score5
WACC7.55%
ROIC/WACCN/A
Cap/Depr(3y)32.19%
Cap/Depr(5y)28.97%
Cap/Sales(3y)3.68%
Cap/Sales(5y)12.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.28%
EPS Next Y-69.76%
EPS Next 2Y-63.12%
EPS Next 3Y-27.26%
EPS Next 5Y-35.06%
Revenue 1Y (TTM)333.49%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%1682.03%
Revenue Next Year-53.12%
Revenue Next 2Y-30.63%
Revenue Next 3Y-42.95%
Revenue Next 5Y-18.4%
EBIT growth 1Y48.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-210.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-215.33%
OCF growth 3YN/A
OCF growth 5YN/A